Retraction notice to "Uptake pathways of cell-penetrating peptides in the context of drug delivery, gene therapy, and vaccine development" [Cellular Signalling 117 (2024) 111116].

Cell-penetrating peptides (CPPs) are the research world’s favorite molecular couriers. They shuttle everything from small molecules to genetic cargo across cell membranes. But this week, the journal Cellular Signalling retracted a 2024 review that dove into how these peptides get inside cells—and what that means for gene therapy, vaccine development, and targeted delivery.

Here’s the quick version: The original article, written by Dowaidar M from King Fahd University, tried to map out the current understanding of CPP uptake pathways. Now, the publication has been formally pulled. The journal didn’t spell out the details, but the article is no longer considered part of the scientific record.

What’s the upshot for peptide researchers?

Key takeaway: One paper down, but the potential of cell-penetrating peptides in delivery science is just getting started. Researchers can keep tabs on new findings and explore foundational work over at the peptide research index.

If you’re sourcing CPPs or other research compounds, the vendor directory remains a solid starting point. The retraction changes nothing about the excitement or opportunity in this space. Stay sharp, stay curious, and keep reading.